Lung Cancer Trials Ask AI to find trials
CompletedNot applicableNCT03116633
Official study title

Concordance of Inivata Liquid Biopsy With Standard Tissue Biopsy

Study summary

This study aims to look at a comparison of liquid biopsy (blood sample) analysis compared with tissue biopsy in patients with advanced lung cancer

Ask AI to explain this study
Start here

Key things to know

Main goalNot specified

This describes the study’s primary purpose.

What is being studiedNot specified

The study team can explain what participation involves.

Who it may be forNon-small cell lung cancer (NSCLC)

These are broad labels—not an eligibility decision.

Checked against the public recordLast updated May 16, 2019 · Source: ClinicalTrials.gov

Is enrollment open?Completed

Ask the study team to confirm whether enrollment is open.

What kind of study?Not applicable

Observational

Where is it offered?6 U.S. locations

Locations may change over time.

Who runs it?Inivata

Study sponsor

01
Study overview

What this study is about

Purpose
Not specified
Study type
Observational
Phase
Not applicable
Sponsor
Inivata
Interventions being studied
Not specified
02
Explore related studies

How this study is categorized

These labels come from structured fields and exact terms in the public record.

Cancer type
Non-small cell lung cancer (NSCLC)→
03
Public criteria

Who may be able to participate

The sponsor separates these requirements into two groups. You do not need to interpret them alone—use them to guide a conversation with the study team.

Requirements people may need to meetInclusion criteria
  • Written, signed and dated informed consent
  • Male \& female patients aged 18 years and over diagnosed with stage IIIb/IV non-squamous NSCLC.
  • Patients intended to initiate first-line treatment (Arms A and B)
  • Patients who plan to have or have had a recent tumor tissue biopsy taken as part of their standard of care (Arm A)
  • Patient must understand and be able, willing and likely to fully comply with all study procedures and restrictions.
Reasons someone may not be able to joinExclusion criteria
  • Patients who have received any approved or experimental cancer therapy since their most recent NSCLC tissue biopsy
  • Any history of metastatic cancer.
  • Previous malignancy in the last 2 years (except basal cell carcinoma of the skin or pre-invasive carcinoma of the cervix).
  • Patient with a severe acute or chronic medical or psychiatric condition or laboratory abnormality

Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.

04
Study sites

U.S. locations

  • Mercy Hospital Cancer Center/Clinical ResearchFort Smith, Arkansas
  • Mercy Cancer CenterJoplin, Missouri
  • Mercy ClinicSpringfield, Missouri
  • Mercy Clinic Oncology & HematologyOklahoma City, Oklahoma
  • Lehigh Valley Health NetworksAllentown, Pennsylvania
  • Gibbs Cancer Center & Research InstituteSpartanburg, South Carolina

Source and freshness
Processed from ClinicalTrials.gov. Last public update: May 16, 2019. Always confirm current availability with the study team.

View original record ↗